Monoclonal antibodies (mAbs) with the ability to block the PD-1/PD-L1 axis, either binding to PD-1 (nivolumab, pembrolizumab) or PD-L1 (atezolizumab, durvalumab), are able to reverse this immunosuppressive state and obtain efficient anti-cancer immune responses (reviewed in [5]). This evidence concerns the gene CD274 and cancer.